MARTINSRIED, Germany, Feb. 20, 2009 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2008 on February 26, 2009 at 7:30 a.m. CET.
MorphoSys will hold its Analyst and Press Conference at the Hotel "Hessischer Hof" in Frankfurt, Germany. Additionally, the Management Team of MorphoSys AG will host a conference call and audio webcast to present MorphoSys's Annual Financial Results 2008 and provide an outlook for 2009.
DATE: Thursday, 26th February 2009 TIME: 14:00 p.m. CET DIAL IN No: +49 (0) 69 710491462 (listen-only) UK RESIDENTS: +44 (0) 1212 604860 US RESIDENTS: +1 (1) 866 347 1957
The call will be hosted by:
Dr. Simon Moroney, Chief Executive Officer Dr. Arndt Schottelius, Chief Development Officer Dave Lemus, Chief Financial Officer
We request that you call the number above up to 10 minutes early to ensure a prompt start and a secure line.
MorphoSys AG offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com
The presentation slides will be available on the Company's website.
A slide-synchronized audio replay of the conference will be available following the live event on www.morphosys.com
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL(r), HuCAL GOLD(r), HuCAL PLATINUM(r) and RapMAT(r) are registered trademarks of MorphoSys AG
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Attachments: